Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
Pfizer filed its bivalent COVID-19 vaccine tailored to the BA.4/BA.5 Omicron subvariants in Japan on September 13, a day after the company earned approval for its BA.1-based jab in the country. The new bivalent mRNA vaccine is based on the…
To read the full story
Related Article
- Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
- MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
- Comirnaty Bags Special Approval in Japan for Kids Aged 6 Months to 4 Years
October 6, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
- Japan Panel to Discuss Comirnaty for Kids Aged 6 Months to 4 Years on Oct. 5
September 29, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
- Pfizer Discussing Filing of BA.5-Based Vaccine with Japanese Authorities
September 1, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
BUSINESS
- Roche Proposes Ex-Takeda CEO Weber for Board
September 24, 2026
- Astellas Starts Setidegrasib PIII in KRAS G12D-Mutated NSCLC
September 24, 2026
- Otsuka’s Antisense Drug Hits PIII Goal in FUS-ALS
September 24, 2026
- EU Panel Backs Enhertu for Adjuvant Use in HER2-Positive Breast Cancer
September 24, 2026
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…